<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117618">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01842269</url>
  </required_header>
  <id_info>
    <org_study_id>223KTP12003</org_study_id>
    <nct_id>NCT01842269</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of My-Rept® Tablet Versus My-Rept® Capsule in Combination With Tacrolimus in Kidney Transplant Patients</brief_title>
  <acronym>My-Rept®_KT_P4</acronym>
  <official_title>Open Label, Randomized, Multi-center, Phase 4 Trial to Evaluate the Efficacy and Safety of My-Rept® Tablet(Mycophenolate Mofetil 500mg/Tab.) Versus My-Rept® Capsule(Mycophenolate Mofetil 250mg/Cap.) in Combination With Tacrolimus for 26 Weeks in Kidney Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of My-Rept® Tablet(Mycophenolate Mofetil 500mg/Tab.) versus My-Rept®
      Capsule(Mycophenolate Mofetil 250mg/Cap.) in Combination with Tacrolimus in Kidney
      Transplant Patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of efficacy failure</measure>
    <time_frame>up to 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>efficacy failure=acute rejection by kidney biopsy,graft loss, death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of acute rejection by kidney biopsy</measure>
    <time_frame>up to 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival with no graft loss</measure>
    <time_frame>up to 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR(using by MDRD method)</measure>
    <time_frame>up to 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>up to 26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Rate of adverse events
Evaluated safety parameters included: Physical examination, laboratory test, etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Primary Kidney Transplantation</condition>
  <condition>Secondary Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>My-Rept® Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>My-Rept® Tablet, Mycophenolate Mofetil 500mg, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>My-Rept® Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>My-Rept® Capsule, Mycophenolate Mofetil 250mg, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil 500mg</intervention_name>
    <arm_group_label>My-Rept® Tablet</arm_group_label>
    <other_name>My-Rept® Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil 250mg</intervention_name>
    <arm_group_label>My-Rept® Capsule</arm_group_label>
    <other_name>My-Rept® Capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 20 years or older.

          2. Patient who receive primary or secondary kidney transplantation from living or
             brain-dead donor .

          3. Patient who receive age 20 years or older donor.

          4. Willing and able to provide written informed consent.

        Exclusion Criteria:

          1. Cold Ischemia Time &gt; 30 hours.

          2. Patient who receive HLA-identical donor.

          3. Patient with dual kidney transplantation recipient or have history of other organ
             transplantation in past or current.

          4. Patient who receive extra-renal solid organ or bone marrow stem cell transplantation.

          5. Patient who receive kidney transplantation from non-heart beating cadaveric
             donor(organ donor after cardiac death

          6. Patient who receive kidney transplantation from ABO blood type mismatching donor or
             lymphocyte cross matching (LCM) positive donor.

          7. Patient with cancer within 5 years, except cured skin cancer patient(Squamous cell or
              basal cell carcinoma)

          8. Positive in serology test(HIV, HBsAg, HCV) in recipients and/or donor.

          9. Patient with Severe gastrointestinal disease in screening period by investigator's
             decision.

         10. Patient with systemic severe infection requiring treatment (able to transplantation
             after completely disappear or is controlled infection)

         11. Liver cirrhosis, clinically significant portal hypertension or other moderate to
             severe liver disease.

         12. Defined by the following laboratory parameters before screening period

               1. One of liver function test(AST, ALT, ALP, Total Bilirubin)results increased more
                  than 3 times upper limit of normal range

               2. WBC &lt;2,500/mm3, Platelet &lt;75,000/mm3

         13. Acute (within 4 weeks) or chronic(need to treatments) allergic/hypersensitivity
             reaction in the history of Investigational drugs (ex, mycophenolate acid or
             tacrolimus, etc.) or additives.

         14. Administration of other Investigational drugs and/or immunosuppressants within 28days
             before screening period (except allowed immunosuppressants in protocol)

         15. Women in pregnant or breast-feeding or don't using adequate contraception.

         16. Patient has conversation impairment because alcohol or drugs addiction history within
             6months or mental illness, etc.

         17. In investigator's judgment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Seun Kim, Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu Seun Kim, Ph. D</last_name>
    <phone>+82-2-2228-2115</phone>
    <email>yukim@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maryknoll Medical Center</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Ryeol Lee, Ph D.</last_name>
      <phone>+82-51-461-2658</phone>
      <email>egis70@naver.com</email>
    </contact>
    <investigator>
      <last_name>Dong Ryeol Lee, Ph. D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chunbuk National University Hospital</name>
      <address>
        <city>Chonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baik Hwan Cho, Ph. D</last_name>
      <phone>+82-63-250-1579</phone>
      <email>chobh@jbnu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Baik Hwan Cho, Ph. D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jongwon Park, Ph.D</last_name>
      <phone>+82-530-620-3849</phone>
      <email>jwpark@med.yu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jongwon Park, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chan-Duck Kim, Ph.D</last_name>
      <phone>+82-53-420-5560</phone>
      <email>drcdkim@knu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Chan-Duck Kim, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wonkwang University School of Medical &amp; Hospital</name>
      <address>
        <city>Iksan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung Jun So, Ph. D</last_name>
      <phone>+82-63-859-1494</phone>
      <email>sobjun@wku.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Byung Jun So, Ph. D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bundang CHA Medical Center</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Jin Kim, MS</last_name>
      <phone>+82-31-780-5254</phone>
      <email>Dicey97@cha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Soo Jin Kim, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Seun kim, Ph. D</last_name>
      <phone>+82-2-2228-2115</phone>
      <email>yukim@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Yu Seun Kim, Ph. D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Man Ki Ju, Ph. D</last_name>
      <phone>+82-2-2228-2105</phone>
      <email>mkju@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Man Ki Ju, Ph. D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kandong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Lee, Ph. D</last_name>
      <phone>+82-2-2224-2222</phone>
      <email>slee@hallym.or.kr</email>
    </contact>
    <investigator>
      <last_name>Samuel Lee, Ph. D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang-Kwan Oh, Ph. D</last_name>
      <phone>+82-31-219-5755</phone>
      <email>ohck@ajou.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Chang-Kwan Oh, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Rae Cho, Ph. D</last_name>
      <phone>+82-52-250-7004</phone>
      <email>hrcho@uuh.ulsan.kr</email>
    </contact>
    <investigator>
      <last_name>Hong Rae Cho, Ph. D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 12, 2013</lastchanged_date>
  <firstreceived_date>April 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mycophenolate Mofetil</keyword>
  <keyword>MMF</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
